PTC Therapeutics, Inc. $PTCT Shares Acquired by Profund Advisors LLC

Profund Advisors LLC raised its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 56.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,877 shares of the biopharmaceutical company’s stock after purchasing an additional 12,904 shares during the quarter. Profund Advisors LLC’s holdings in PTC Therapeutics were worth $2,324,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its position in PTC Therapeutics by 16.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 151 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of PTC Therapeutics by 1.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 13,730 shares of the biopharmaceutical company’s stock worth $1,120,000 after buying an additional 237 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of PTC Therapeutics by 8.5% in the first quarter. PNC Financial Services Group Inc. now owns 3,128 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 244 shares in the last quarter. State of Wyoming grew its stake in shares of PTC Therapeutics by 15.3% in the third quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 260 shares in the last quarter. Finally, Vise Technologies Inc. raised its stake in PTC Therapeutics by 3.1% in the 3rd quarter. Vise Technologies Inc. now owns 8,826 shares of the biopharmaceutical company’s stock worth $572,000 after purchasing an additional 266 shares in the last quarter.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $59.97 on Monday. The business has a 50-day simple moving average of $65.36 and a 200 day simple moving average of $70.78. PTC Therapeutics, Inc. has a one year low of $58.80 and a one year high of $90.87. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of -42.84, a PEG ratio of 1.81 and a beta of 0.52.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the consensus estimate of $0.14 by ($0.76). The firm had revenue of $357.81 million during the quarter, compared to analysts’ expectations of $306.43 million. During the same period in the previous year, the business posted $0.20 earnings per share. The firm’s revenue was up 69.6% on a year-over-year basis. On average, sell-side analysts expect that PTC Therapeutics, Inc. will post 1.19 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Royal Bank Of Canada increased their price objective on shares of PTC Therapeutics from $75.00 to $77.00 and gave the stock a “sector perform” rating in a research note on Friday. TD Cowen boosted their price objective on shares of PTC Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Friday. UBS Group assumed coverage on PTC Therapeutics in a research note on Thursday, October 15th. They issued a “buy” rating and a $90.00 price target on the stock. Leerink Partners initiated coverage on PTC Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $98.00 price target for the company. Finally, Cantor Fitzgerald raised their price objective on PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.64.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
• Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
• Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
• Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

Insider Buying and Selling

In other news, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total value of $781,920.00. Following the sale, the director directly owned 22,500 shares of the company’s stock, valued at approximately $1,466,100. This represents a 34.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the business’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $59.61, for a total transaction of $149,025.00. Following the transaction, the director owned 1,291,594 shares of the company’s stock, valued at $76,991,918.34. This trade represents a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 77,370 shares of company stock worth $5,322,261. Insiders own 5.30% of the company’s stock.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.